Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

318 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test compare the Stentys Stent with the Multi-Link Vision™ stent system (Abbott Vascular Inc.)in patients with a heart attack. It is expected that the Stentys stent is not worse than the Vision stent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)

NCT01008085

STEMI

COMPLETED PHASE3

Evaluation of Neointimal Coverage of EES and BMS After Implantation in STEMI Patients by Optical Coherence Tomography

NCT01875835

Acute Myocardial Infarction

TERMINATED NA

Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT

NCT01405287

Coronary Artery Disease Atherosclerosis Acute Coronary Syndrome (ACS) +1 more

COMPLETED PHASE2

Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII

NCT02093845

Coronary Artery Disease Ischemic Heart Disease

UNKNOWN NA

Xience or Vision Stent Management of Angina in the Elderly

NCT02198716

Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery disease continues to be the most common cause of morbidity and mortality in the occidental world. Treatment of coronary atherosclerotic disease has been significantly advanced by interventional cardiology, and in particular the advent of coronary arterial stents. In comparison to angioplasty alone, stents have reduced the incidence of angiographic as well as clinical restenosis, the recurrence of angina, the need for coronary arterial bypass graft (CABG) surgery, the need for repeat revascularization and the occurrence of major adverse cardiac events (MACE).However,problems remain due to failure to achieve optimal stent apposition and normal myocardial reperfusion. Early stent malapposition may be due to incomplete expansion or undersizing of balloon-expandable stents. Several studies have emphasized the importance of early malapposition in the setting of ST elevation MI, in which substantial thrombotic burden and the presence of diffuse vasoconstriction may be contributory. The Stentys Coronary Stent System includes a self-expanding bare metal (nitinol) stent on a rapid exchange (RX) delivery system. In view of the theoretical implications of malapposition, the self-expanding property may offer a potential benefit.

This study is designed to evaluate the safety and effectiveness of the Stentys Coronary Stent System in the treatment of de novo stenotic lesions in coronary arteries in patients undergoing primary revascularization due to AMI as compared to the Multi-Link Vision™ coronary stent system (Abbott Vascular Inc. The study is powered for non-inferiority of the Stentys Coronary Stent System compared to the Vision Stent System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STENTYS self-apposing stent

Intervention to treat STEMI with the STENTYS self-apposing stent

Group Type EXPERIMENTAL

STENTYS self-apposing stent

Intervention Type DEVICE

Intervention to treat STEMI with the STENTYS self-apposing stent

VISION balloon-expandable stent

STEMI treatment with a VISION balloon-expandable stent

Group Type ACTIVE_COMPARATOR

VISION balloon-expandable stent

Intervention Type DEVICE

STEMI treatment with a VISION balloon-expandable stent

\--------------------------------------------------------------------------------

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STENTYS self-apposing stent

Intervention to treat STEMI with the STENTYS self-apposing stent

Intervention Type DEVICE

VISION balloon-expandable stent

STEMI treatment with a VISION balloon-expandable stent

\--------------------------------------------------------------------------------

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject ≥ 18 years old.
2. Subject experiencing clinical symptoms consistent with AMI of \>30 min. in duration.
3. ST elevation ≥1 mm in ≥2 contiguous leads or new left bundle branch block, or true posterior MI with ST depression of ≥1 mm in ≥2 contiguous anterior leads.
4. Symptom duration is \<12 hours prior to signing informed consent.
5. Subject should be in catheterization laboratory and procedure started within 2 hours of consent.
6. Patient provides written informed consent.
7. Patient agrees to all required follow-up procedures and visits.

1. Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated use of stenting.
2. The vessel diameter is either known or expected to be 2.5-4.0mm, without excessive tortuosity or diffuse distal disease.
3. Lesion length ≥12mm and ≤ 23mm

\-

Exclusion Criteria

1. Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
2. A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
3. Female patients of childbearing potential known to be pregnant.
4. Patients undergoing cardiopulmonary resuscitation.
5. Cardiogenic shock (SBP \<80 mmHg for \>30 minutes, or requiring IV pressors or emergency IABP for hypotension).
6. The subject requires multivessel PCI at time of index procedure or any staged procedure of the target vessel within 9 months or any non-target vessel within 30 days post-procedure.
7. The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.). Thrombus aspiration may be used per operator discretion.
8. Attempted thrombolysis.
9. Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
10. Concurrent medical condition with a life expectancy of less than 12 months.
11. Known left ventricular ejection fraction (LVEF) \< 25% at the most recent evaluation (prior to the index hospitalization).
12. History of cerebrovascular accident or transient ischemic attack in the last 6 months.
13. Active peptic ulcer or active gastrointestinal (GI) bleeding.
14. History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
15. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.
16. Known serum creatinine level \> 2.5 mg/dl, eGFR \<30, or hemodialysis dependent.

1. Unprotected left main coronary artery disease (obstruction greater than 60% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).
2. Multi-vessel intervention required during the index procedure.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No